Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Sarah Aebersold Biography and Net Worth

VP of BioLife Solutions

Presently, Sarah Aebersold is Vice President-Human Resources for BioLife Solutions, Inc.

She received a graduate degree from Seattle University.

What is Sarah Aebersold's net worth?: The estimated net worth of Sarah Aebersold is at least $1.04 million as of April 1st, 2024. Ms. Aebersold owns 65,843 shares of BioLife Solutions stock worth more than $1,044,270 as of April 19th. This net worth evaluation does not reflect any other assets that Ms. Aebersold may own. Learn More about Sarah Aebersold's net worth.
How old is Sarah Aebersold?: Ms. Aebersold is currently 47 years old. There are 7 older executives and no younger executives at BioLife Solutions. The oldest executive at BioLife Solutions is Mr. Roderick de Greef, CEO & Chairman, who is 64 years old. Learn More on Sarah Aebersold's age.
How do I contact Sarah Aebersold?: The corporate mailing address for Ms. Aebersold and other BioLife Solutions executives is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. BioLife Solutions can also be reached via phone at (425) 402-1400 and via email at [email protected]. Learn More on Sarah Aebersold's contact information.
Has Sarah Aebersold been buying or selling shares of BioLife Solutions?: Over the course of the past ninety days, Sarah Aebersold has sold $70,600.00 of BioLife Solutions stock. Most recently, Sarah Aebersold sold 4,000 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $17.65, for a transaction totalling $70,600.00. Following the completion of the sale, the insider now directly owns 65,843 shares of the company's stock, valued at $1,162,128.95. Learn More on Sarah Aebersold's trading history.
Who are BioLife Solutions' active insiders?: BioLife Solutions' insider roster includes Sarah Aebersold (VP), Todd Berard (CMO), Roderick de Greef (CFO), Karen Foster (Insider), Andrew Hinson (Director), Aby Mathew (VP), Michael Rice (CEO), Joseph Schick (Director), Marcus Schulz (CRO), and Troy Wichterman (CFO). Learn More on BioLife Solutions' active insiders.
Are insiders buying or selling shares of BioLife Solutions?: In the last twelve months, BioLife Solutions insiders bought shares 5 times. They purchased a total of 1,055,603 shares worth more than $12,648,274.13. In the last twelve months, insiders at the medical equipment provider sold shares 86 times. They sold a total of 211,175 shares worth more than $3,306,533.24. The most recent insider tranaction occured on April, 15th when CMO Todd Berard sold 10,000 shares worth more than $156,700.00. Insiders at BioLife Solutions own 2.7% of the company. Learn More about insider trades at BioLife Solutions.
Information on this page was last updated on 4/15/2024.

Sarah Aebersold Insider Trading History at BioLife Solutions

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2024	Sell	4,000	$17.65	$70,600.00	65,843
2/21/2024	Sell	58	$17.35	$1,006.30	41,806
1/23/2024	Sell	336	$17.11	$5,748.96	41,864
7/24/2023	Sell	462	$19.50	$9,009.00	43,983
4/19/2023	Sell	292	$19.33	$5,644.36	42,059
1/19/2023	Sell	374	$22.93	$8,575.82	44,167
11/10/2022	Sell	38	$23.16	$880.08	32,091
10/28/2022	Sell	272	$21.76	$5,918.72	32,129
8/10/2022	Sell	40	$23.17	$926.80	32,401
7/22/2022	Sell	252	$17.85	$4,498.20	32,441
5/13/2022	Sell	40	$12.32	$492.80	32,693
4/21/2022	Sell	325	$13.94	$4,530.50	32,733
2/10/2022	Sell	197	$29.38	$5,787.86
1/20/2022	Sell	332	$30.24	$10,039.68
10/20/2021	Sell	272	$42.34	$11,516.48

Sarah Aebersold Buying and Selling Activity at BioLife Solutions

BioLife Solutions Company Overview

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Today's Range

Now: $15.64

$15.52

$16.01

50 Day Range

MA: $17.50

$15.14

$18.82

2 Week Range

Now: $15.64

$8.92

$24.50

Volume

79,026 shs

Average Volume

401,084 shs

Market Capitalization

$708.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad